ALANASE
Beclometasone dipropionate Aqueous Nasal Spray
50 µg & 100 µg per actuation

Presentation
ALANASE Aqueous Nasal Spray (50 micrograms per actuation) is an almost white opaque suspension of microfine beclometasone dipropionate delivered by a metering, atomising pump. Each 100 mg spray delivered by the nasal applicator contains 50 µg beclometasone dipropionate.

ALANASE 100 Aqueous Nasal Spray (100 micrograms per actuation) is an almost white opaque suspension of microfine beclometasone dipropionate delivered by a metering, atomising pump. Each 100 mg spray delivered by the nasal applicator contains 100 µg beclometasone dipropionate.

Uses
Actions
Following topical administration beclometasone 17, 21-dipropionate (BDP) produces potent anti-inflammatory and vaso-constrictor effects.

BDP is a pro-drug with weak corticosteroid receptor binding affinity. It is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate (B-17-MP), which has high topical anti-inflammatory activity.

Beclometasone dipropionate offers a preventative background treatment for hayfever when taken prior to allergen challenge. After which with regular use, BDP can continue to prevent allergy symptoms from reappearing.

Pharmacokinetics
Absorption
Following intranasal administration of BDP in healthy males, the systemic absorption was assessed by measuring the plasma concentrations of its active metabolite B-17-MP, for which the absolute bioavailability following intranasal administration is 44% (95% CI 28%, 70%). After intranasal administration, < 1% of the dose is absorbed by the nasal mucosa. The remainder after being cleared from the nose, either by drainage or mucociliary clearance, is available for absorption from the gastrointestinal tract. Plasma B-17-MP is almost entirely due to conversion of BDP absorbed from the swallowed dose.

Following oral administration of BDP in healthy males, the systemic absorption was also assessed by measuring the plasma concentrations of its active metabolite B-17-MP, for which the absolute bioavailability following oral administration is 41% (95% CI 27%, 62%).

Metabolism
BDP is cleared very rapidly from the circulation and plasma concentrations are undetectable (< 50pg/mL) following oral or intranasal dosing. There is rapid metabolism of the majority of the swallowed portion of BDP during its first passage through the liver. The main product of metabolism is the active metabolite (B-17-MP). Minor inactive metabolites, beclometasone-21-monopropionate (B-21-MP) and beclometasone (BOH), are also formed but these contribute little to systemic exposure.

Distribution
The tissue distribution at steady-state for BDP is moderate (20L) but more extensive for B-17-MP (424L). Plasma protein binding of BDP is moderately high (87%).
Elimination
The elimination of BDP and B-17-MP are characterised by high plasma clearance (150 and 120L/hour) with corresponding terminal elimination half-lives of 0.5 hours and 2.7 hours. Following oral administration of tritiated BDP, approximately 60% of the dose was excreted in the faeces within 96 hours mainly as free and conjugated polar metabolites. Approximately 12% of the dose was excreted as free and conjugated polar metabolites in the urine.

Preclinical safety data
No clinically relevant findings were observed in preclinical studies.

Indications
ALANASE Aqueous Nasal Spray (50 µg per actuation) is indicated for the short-term prevention and treatment of seasonal allergic rhinitis (hay fever).

ALANASE 100 Aqueous Nasal Spray (100 µg per actuation) is indicated for the prevention and treatment of seasonal and perennial allergic rhinitis and vasomotor rhinitis.

ALANASE 100 can significantly delay the recurrence of nasal polyps in those patients who have undergone nasal polypectomy. In those polyps that do recur, ALANASE 100 can suppress their increase in size.

Dosage and Administration
ALANASE and ALANASE 100 Aqueous Nasal Spray should be shaken before use.

ALANASE (50 micrograms per actuation)
For adults and children over 12 years of age:
Initially one or two sprays into each nostril twice a day (morning and night), then after 2 to 3 days, one spray into each nostril twice a day.

Do not use ALANASE (50 µg per actuation) for children under 12 years of age without first consulting with a doctor.

If hayfever symptoms do not improve within 7 days of treatment with ALANASE, consult with a doctor.

ALANASE 100 (100 µg per actuation)
For adults and children over 6 years of age:
The recommended dosage is one spray into each nostril twice daily.

For some patients, a dosage regimen of 50 micrograms into each nostril three or four times daily may be preferred. Total daily administration should not normally exceed 400 micrograms.

For full therapeutic benefit regular usage is essential. The co-operation of the patient should be sought to comply with the regular dosage schedule and it should be explained that maximum relief may not be obtained within the first few applications.

For children under six years old, there are insufficient clinical data to recommend use.

ALANASE and ALANASE 100 Aqueous Nasal Spray's are for administration by the intra-nasal route only.

Contraindications
Hypersensitivity to the active substance or any of the excipients (see FURTHER INFORMATION).
Warnings and Precautions

Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations. Potential systemic effects may include Cushing’s syndrome, Cushingoid features, growth retardation in children and adolescents (see WARNINGS and PRECAUTIONS, Paediatric Use section), cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).

Growth retardation has been reported in children receiving nasal corticosteroids at licensed doses. It is recommended that the height of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of nasal corticosteroid, if possible to the lowest dose at which effective control of symptoms is maintained. In addition, consideration should be given to referring the patient to a paediatric specialist.

Treatment with higher than recommended doses may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. Care must be taken while transferring patients from systemic steroid treatment to ALANASE and ALANASE 100 if there is any reason to suppose that their adrenal function is impaired.

Infections of the nasal passages and paranasal sinuses should be appropriately treated but do not constitute a specific contraindication to treatment with ALANASE and ALANASE 100.

Although ALANASE and ALANASE 100 will control seasonal allergic rhinitis in most cases, an abnormally heavy challenge of summer allergens may in certain instances necessitate appropriate additional therapy particularly to control eye symptoms.

Paediatric Use
Continuous long term treatment of children is not recommended.

Use During Pregnancy and Lactation

Pregnancy
There is inadequate evidence of safety in human pregnancy. Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human foetus. It should be noted, however, that the foetal changes in animals occur after relatively high systemic exposure. ALANASE and ALANASE 100 delivers beclometasone dipropionate directly to the nasal mucosa and so minimises systemic exposure.

The use of beclometasone dipropionate should be avoided during pregnancy unless thought essential by the doctor.

Breast-feeding
No specific studies examining the transference of beclometasone dipropionate into the milk of lactating animals have been performed. It is reasonable to assume that beclometasone dipropionate is secreted in milk but at the dosages used for direct intra-nasal application, there is low potential for significant levels in breast milk. The use of beclometasone dipropionate in mothers breast feeding their babies requires that the therapeutic benefits of the medicine be weighed against the potential hazards to the mother and baby.

Effects on Ability to Drive and Use Machines
Not relevant.
Adverse Effects

Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 and <1/10), uncommon (≥ 1/1000 and <1/100), rare (≥ 1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports. Very common, common and uncommon reactions were generally determined from clinical trial data. Rare and very rare reactions were generally determined from spontaneous data. In assigning adverse reaction frequencies, the background rates in placebo groups were not taken into account, since these rates were generally comparable to those in the active treatment group.

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse Event</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td>Hypersensitivity reactions including:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rash, urticaria, pruritis, erythema.</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Angioedema</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Dyspnoea and/or bronchospasm</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Anaphylactoid/anaphylactic reactions</td>
<td>Very rare</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Unpleasant taste, unpleasant smell.</td>
<td>Common</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Glaucoma, raised intraocular pressure, cataract.</td>
<td>Very rare</td>
</tr>
<tr>
<td>Respiratory, Thoracic &amp; Mediastinal disorders</td>
<td>Epistaxis, nasal dryness, nasal irritation, throat dryness, throat irritation.</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Nasal septum perforation.</td>
<td>Very rare</td>
</tr>
</tbody>
</table>

Systemic effects of nasal corticosteroids may occur particularly when used at high doses for prolonged periods (see WARNINGS and PRECAUTIONS).

Interactions

No known interactions have been observed.

Overdosage

The only harmful effect that follows inhalation of large amounts of the medicine over a short time period is suppression of Hypothalamic-Pituitary-Adrenal (HPA) function. No special emergency action need be taken. Treatment with ALANASE and ALANASE 100 Aqueous Nasal Spray should be continued at the recommended dose. HPA function recovers in a day or two.

There is no specific treatment for an overdose of beclometasone dipropionate. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

For further advice on management of overdose please contact the National Poisons Information Centre (0800 POISON or 0800 764 766).

Pharmaceutical Precautions

ALANASE and ALANASE 100 should be protected from light and stored below 25°C. Do not refrigerate.

Discard three months after first using the spray.
**Medicine Classification**

ALANASE: Pharmacy Medicine.

ALANASE 100: Prescription Medicine.

**Package Quantities**

ALANASE and ALANASE 100 are supplied in amber glass bottles fitted with a metering, atomising pump and nasal applicator. Both dosage strengths provide 200 actuations.

**Further Information**

List of excipients: benzalkonium chloride, phenethyl alcohol, polysorbate, dispersible cellulose, glucose (anhydrous) and purified water.

**Name and Address**

Mylan New Zealand Limited  
PO Box 11-183  
Ellerslie  
AUCKLAND  
Telephone 09-579-2792

**Date of Preparation**

16 June 2015